Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
CAMBRIDGE, Mass., Nov. 20, 2019 /PRNewswire/ — Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next generation, transformative cancer treatments, today announced the completion of its $56 million Series A financing. The company is developing novel…
Comments Off on Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines